The NovaSure V5 global endometrial ablation device received approval in Canada and Europe. Credit: Hologic / Business Wire.

Hologic has received approval for its NovaSure V5 global endometrial ablation (GEA) device to be used in Canada and Europe.

The new version of the device has improved features to help treat several cervical and uterine anatomies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

NovaSure V5 includes an updated cervical seal, which features EndoForm technology and is designed to increase the device’s sealing surface as well as accommodate a range of cervical canals and anatomies.

Its AccuSheath markings will enable improved accuracy and confidence for the seating and fundal placement, stated the company.

Furthermore, the device features SureClear technology, a fluid removal system that offers integrated suction through the array by constant tissue contact while eliminating ablation byproducts such as vapour and fluid.

See Also:

In addition, the NovaSure device offers an endometrial ablation procedure to treat abnormal uterine bleeding.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Hologic international group president Jan Verstreken said: “Since its launch over 20 years ago, we have constantly listened to our customers’ feedback, which has driven continuous design improvements for NovaSure.

“This has enabled us to develop our technology to further meet their needs and those of the women they treat, ultimately delivering better outcomes for these women.”

Last July, Hologic launched the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay and Novodiag RESP-4 molecular diagnostic test in the European Union (EU).

The assays were developed to detect and differentiate four respiratory viruses that can have similar clinical symptoms, namely influenza A (Flu A), influenza B (Flu B), SARS-CoV-2 and respiratory syncytial virus (RSV).